u l'	4
V	(Z
- ₹ ∨	- •

Office Action Summary

Application No.

08/956,277

Applicant(s)

Examiner

Group Art Unit

**Andrulis** 

·	Jerome D. Goldberg	1205
Responsive to communication(s) filed on		
☐ This action is <b>FINAL</b> .		# 2
☐ Since this application is in condition for allowance excelling accordance with the practice under <i>Ex parte Quayle</i> ,		n as to the merits is closed
A shortened statutory period for response to this action is is longer, from the mailing date of this communication. Fai application to become abandoned. (35 U.S.C. § 133). Ext. 37 CFR 1.136(a).	lure to respond within the period	for response will cause the
Disposition of Claims		94 ·
	is/are p	ending in the application.
Of the above, claim(s)	is/are wi	thdrawn from consideration.
Claim(s)	is	/are allowed.
Claim(s)	is	/are rejected.
Claim(s)		
Application Papers  See the attached Notice of Draftsperson's Patent Draftsperson's Pate	bjected to by the Examiner.  is approved  er.  prity under 35 U.S.C. § 119(a)-(a) ies of the priority documents have I Number) the International Bureau (PCT R	re been ule 17.2(a)).
Attachment(s)		
<ul> <li>Notice of References Cited, PTO-892</li> <li>□ Information Disclosure Statement(s), PTO-1449, Pap</li> <li>□ Interview Summary, PTO-413</li> <li>□ Notice of Draftsperson's Patent Drawing Review, PT</li> <li>□ Notice of Informal Patent Application, PTO-152</li> </ul>		
SEE OFFICE ACTION	ON THE FOLLOWING PAGES	

Art Unit: 1205

Claims 1-20 are directed to enhanced combination of a tumor necrosis factor inhibitor and a compound selected from transcriptase inhibitor, protease inhibitor, a gene inhibitor, myristoylation inhibitors, cell-virus binding inhibitor, LTR promoter site inhibitors, ribosome in activators or platelet aggregation inhibition. Applicants are, therefore, required to elect a single enhanced combination of one tumor necrosis factor with one compound inhibitor and to add a claim to the elected enhanced combination.

The several inventions above are independent and distinct, each from the other, as they have acquired a separate status in the art of treating AIDS as a separate subject matter for inventive effect and require independent searches. It is noted that reference to one enhanced combination of drugs would not be a reference to another enhanced combination of drugs under 35 U.S.C. 103. Further, the claims read on a multitude of enhanced combinations of drugs which would require many field of searches that would be an undue burden on the Examiner. Therefore, restriction for examination purposes is proper.

Applicants are required to make a provisional election even though this requirement is traversed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner J.D. Goldberg whose telephone number is (703) 308-4606. The examiner can normally be reached on Monday through Thursday from 9:00AM to 3:00PM.

Serial Number: 956277 Page 3

Art Unit: 1205

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Marianne Cintinis, can be reached on (703) 308-4725. The fax phone number for this Group is (703) 308-4556 or 305-3592.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-1235.

Goldberg/sg

January 30, 1998

JEROME D. GOLDBERG PRIMARY EXAMINER

**GROUP 1200**